Loading
A phase 3 trial of Anlotinib, Dacarbazine in sarcomas, run by Advenchen Laboratories, LLC, now recruiting.
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) is a phase 3 interventional study registered as NCT03016819 by Advenchen Laboratories, LLC, with 325 participants planned, started 2017-08-15 and due to reach its primary completion in 2027-12. Interventions recorded: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg). Conditions listed: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma. No results are recorded here; the registry entry is the source.
Shares Alveolar soft part sarcoma, Anlotinib, Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST).
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Anlotinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.